vTv Therapeutics Inc. (VTVT)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $25.72
- As of
Kresmion compiles this page from VTVT's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
vTv Therapeutics Inc. (VTVT): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-06.
See the full VTVT dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for VTVT on one page. Preview it with sample data, then open it live with a free account.
Preview the VTVT dossierActive events for VTVT
- high13F: funds added
4 tracked funds increased VTVT this 2026Q2, institutional consensus
- medium13F: new position
CITADEL ADVISORS LLC new position in VTVT
- high13F: funds added
3 tracked funds increased VTVT this 2026Q2, institutional consensus
- medium13F: new position
Point72 Asset Management, L.P. new position in VTVT
- medium13F: new position
RENAISSANCE TECHNOLOGIES LLC new position in VTVT
FREE, NO ACCOUNT
Every event on VTVT, as it fires
You are seeing 5 of 12 events recorded on VTVT since 2026-05-31.
The five above landed across 2 days. The other 7 were recorded on 3 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in VTVT (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 918385204 · 2026Q2 | $10.2M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 918385204 · 2026Q2 | $657K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 918385204 · 2026Q2 | $432K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 918385204 · 2026Q2 | $224K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 918385204 · 2026Q2 | $222K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, VTVT
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
VTVT against its peers
VTVT's return on equity of -41.9% ranks in the 64th percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-01-31 and 2025-12-31.
| Metric | VTVT | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 27.6M USD | 11 | 13 |
| Operating margin | n/a | -279.5% | n/a | 11 |
| Net margin | n/a | -240.3% | n/a | 11 |
| Return on equity | -41.9% | -69.9% | 64 | 17 |
Peers (23): NERV, NRXP, UNCY, BDTX, PYPD, VYGR, BETRF, CBUS, ENGN, FHTX, VANI, ANIX, OKUR, IMUX, HUMA, VXRT, LENZ, TVGN, CLLS, AVXL, ICCC, ORGO, NKTX. Left out: TLSA (period gap), RTSN (no annual filing). Fiscal periods ending between 2025-01-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (VTVT: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow VTVT on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to VTVT for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.